Stock A287410 JEISYS MEDICAL INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Jeisys Medical Inc.

Equities

A287410

KR7287410005

Advanced Medical Equipment & Technology

End-of-day quote Korea S.E.
Other stock markets
 23:00:00 27/06/2024 BST 		5-day change 1st Jan Change
12,870 KRW 0.00% Intraday chart for Jeisys Medical Inc. +0.08% +22.69%
06-12 AVAVA, Inc. announced that it has received $35 million in funding from Jeisys Medical Inc., Catalio Capital Management, LP and other investors CI
06-10 Syracuse Subco, Inc proposed to acquire an additional 72.04% stake in Jeisys Medical Inc. for approximately KRW 720 billion. CI

Valuation

Fiscal Period: December 2021 2022 2023 2024 2025 2026
Capitalization 1 552,979 606,355 789,504 970,796 - -
Enterprise Value (EV) 2 531 580.2 763.7 922.4 895.7 844
P/E ratio 43.9 x 22.9 x 32.6 x 24.2 x 19 x 15.6 x
Yield - - - - - -
Capitalization / Revenue 6.8 x 5.2 x 5.52 x 5.12 x 4.44 x 3.76 x
EV / Revenue 6.53 x 4.98 x 5.34 x 4.87 x 4.1 x 3.27 x
EV / EBITDA 21.5 x 15.5 x 18.8 x 16.2 x 12.4 x 9.75 x
EV / FCF 29.6 x 45.2 x 41.5 x 25.4 x 30.3 x 16 x
FCF Yield 3.37% 2.21% 2.41% 3.93% 3.3% 6.25%
Price to Book 11.8 x 7.65 x 8.31 x 7.05 x 5.22 x 3.85 x
Nbr of stocks (in thousands) 71,168 71,168 75,263 75,431 - -
Reference price 3 7,770 8,520 10,490 12,870 12,870 12,870
Announcement Date 03/02/22 07/03/23 14/03/24 - - -
1KRW in Million2KRW in Billions3KRW
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2021 2022 2023 2024 2025 2026
Net sales 1 81.3 116.5 143 189.5 218.7 257.9
EBITDA 1 24.74 37.35 40.58 56.9 72.06 86.55
EBIT 1 22.6 34.31 36.31 52.77 67.14 81.82
Operating Margin 27.8% 29.44% 25.39% 27.85% 30.7% 31.72%
Earnings before Tax (EBT) 1 12.09 34.16 35.5 51.81 66.32 80.86
Net income 1 10.09 27.32 24.8 40.41 51.69 63.08
Net margin 12.41% 23.44% 17.34% 21.33% 23.63% 24.45%
EPS 2 177.0 372.0 322.0 531.3 678.6 826.1
Free Cash Flow 3 17,910 12,823 18,387 36,250 29,540 52,750
FCF margin 22,031.09% 11,001.88% 12,855.42% 19,129.06% 13,506.5% 20,450.26%
FCF Conversion (EBITDA) 72,381.58% 34,327.13% 45,313.72% 63,703.09% 40,992.58% 60,946.01%
FCF Conversion (Net income) 177,457.15% 46,934.57% 74,140.09% 89,695.33% 57,152.97% 83,627.3%
Dividend per Share 2 - - - - - -
Announcement Date 03/02/22 07/03/23 14/03/24 - - -
1KRW in Billions2KRW3KRW in Million
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4
Net sales 1 22.39 25.33 30.77 28.64 31.8 35.16 39.11 39.66 43.96 43.1 43.1 45.7
EBITDA 1 - - - - - - - - 10.03 13.8 15.9 17.4
EBIT 1 5.684 8.549 8.962 7.716 9.087 9.648 10.22 8.829 8.86 11 11 14.1
Operating Margin 25.38% 33.74% 29.12% 26.94% 28.57% 27.44% 26.14% 22.26% 20.16% 25.52% 25.52% 30.85%
Earnings before Tax (EBT) 1 5.909 8.399 9.366 9.111 7.288 8.018 10.13 8.918 8.746 14.2 16.3 18.5
Net income 1 4.576 6.551 7.407 7.211 6.152 6.204 7.95 3.966 6.925 8.5 8.5 10.8
Net margin 20.43% 25.86% 24.07% 25.18% 19.34% 17.64% 20.33% 10% 15.76% 19.72% 19.72% 23.63%
EPS - - - - - - - - 90.00 - - -
Dividend per Share - - - - - - - - - - - -
Announcement Date 03/02/22 10/05/22 11/08/22 10/11/22 07/03/23 11/08/23 09/11/23 14/03/24 10/05/24 - - -
1KRW in Billions
Estimates

Balance Sheet Analysis

Fiscal Period: December 2021 2022 2023 2024 2025 2026
Net Debt 1 - - - - - -
Net Cash position 1 21.9 26.2 25.9 48.4 75.1 127
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow 2 17,910 12,823 18,387 36,250 29,540 52,750
ROE (net income / shareholders' equity) 31.2% 43.2% 28.4% 35.6% 32.2% 29.4%
ROA (Net income/ Total Assets) 17.8% 28.4% 19% 25% 23.4% 21.5%
Assets 1 56.61 96.09 130.2 162 220.6 292.9
Book Value Per Share 3 660.0 1,114 1,262 1,826 2,464 3,343
Cash Flow per Share 3 264.0 329.0 422.0 725.0 747.0 872.0
Capex 1 2.39 12.4 14.3 8.33 27.5 13.5
Capex / Sales 2.94% 10.66% 9.99% 4.4% 12.56% 5.23%
Announcement Date 03/02/22 07/03/23 14/03/24 - - -
1KRW in Billions2KRW in Million3KRW
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Jeisys Medical Inc.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
12,870 KRW
Average target price
14,750 KRW
Spread / Average Target
+14.61%
Consensus

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Other Advanced Medical Equipment & Technology

1st Jan change Capi.
JEISYS MEDICAL INC. Stock Jeisys Medical Inc.
+22.69% 704M
THERMO FISHER SCIENTIFIC Stock Thermo Fisher Scientific
+4.18% 211B
DANAHER CORPORATION Stock Danaher Corporation
+8.00% 185B
INTUITIVE SURGICAL, INC. Stock Intuitive Surgical, Inc.
+31.86% 158B
BOSTON SCIENTIFIC CORPORATION Stock Boston Scientific Corporation
+33.21% 113B
SIEMENS HEALTHINEERS AG Stock Siemens Healthineers AG
+2.28% 64.32B
EDWARDS LIFESCIENCES CORPORATION Stock Edwards Lifesciences Corporation
+21.14% 55.66B
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD. Stock Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
+0.11% 48.41B
AGILENT TECHNOLOGIES, INC. Stock Agilent Technologies, Inc.
-6.76% 37.82B
GE HEALTHCARE TECHNOLOGIES INC. Stock GE HealthCare Technologies Inc.
+0.78% 35.57B
Other Advanced Medical Equipment & Technology
  1. Stock Market
  2. Equities
  3. A287410 Stock
  4. Financials Jeisys Medical Inc.